Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

exalurenPositive

AI Analysis

Summary

Eloxx Pharmaceuticals completed a $66.0 million underwritten public offering and uplit to Nasdaq Capital Market. The company is preparing to initiate a Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome in Q3 2026.

Clinical Trial Data

Phase

Outcome Details

Completed underwritten public offering with uplisting to Nasdaq Capital Market

Importance:7/10

Sentiment:

0.60

public offeringnasdaq uplistingphase 2b trialalport syndromebalance sheet strengthening

Related Companies

$ELOX

Read the original article

Published by PR Newswire Biotech on August 12, 2026 10:00 AM

Read Original